ClinicalTrials.gg
RecruitingNCT07021963Updated Sep 10, 2025

A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy

A Phase 2 interventional study of HRS-1893 Tablet in Hypertrophic Cardiomyopathy, sponsored by Shandong Suncadia Medicine Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies in Cardiomyopathy, Hypertrophic with a site in China — 30 open to participants now, 43 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · China.

Planned enrollment
5th of 39
300 · median 84
Started
2025
with 10 others
Phase 2
4 of 71
2 open now
Primary completion
2027-12
later than 36 of 42 live
Registered
58th of 71
by date
Lead sponsor
7 of 71
Shandong Suncadia Medicine Co., Ltd.

Among the 71 studies in Cardiomyopathy, Hypertrophic with a site in China, this one is the 5th largest by planned enrollment of the 39 interventional ones that give a count, is one of 11 that started in 2025, is one of 4 in phase 2, reaches primary completion later than 36 of the 42 other live ones, and was the 58th registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

30 of the 71 studies in Cardiomyopathy, Hypertrophic with a site in China are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Cardiomyopathy, Hypertrophic with a site in China, or all of them as a file.
02

Study summary

This study mainly evaluates the long-term safety of HRS-1893 in subjects with hypertrophic cardiomyopathy.

03

Conditions studied

  • Hypertrophic Cardiomyopathy
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with hypertrophic cardiomyopathy who have previously completed HRS-1893 related studies.
  2. Female subjects of must have a negative serum pregnancy test within 7 days prior to the first dose and must be non-lactating during the study. Female subjects of childbearing potential and male subjects whose partners are women of childbearing potential must agree to refrain from donating sperm/eggs from the time they sign the form until 3 months after the last dose of trial drug, and to comply with relevant requirements.
  3. Understand the study procedures and methods, voluntarily participate in this trial, and sign the informed consent form in writing.

Exclusion criteria

Exclusion Criteria:

  1. Previous history of coronary artery disease (stenosis of one or more coronary arteries >70%) or myocardial infarction.
  2. Have received medication for negative inotropic other than disopyramide, β-blocker, verapamil, diltiazem 4 weeks before screening.
  3. History of syncope or sustained ventricular tachycardia within 6 months prior to screening.
  4. Other conditions that the investigator considers the subject to be unsuitable for participating in this trial, such as physical or psychological diseases or conditions that may increase the risk of the trial, affect the subject's compliance with the protocol, or affect the subject's completion of the trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Obstructive Hypertrophic Cardiomyopathy Group

    Drug: HRS-1893 Tablet

  • Experimental
    Non-obstructive Hypertrophic Cardiomyopathy Group

    Drug: HRS-1893 Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs).

    Time frame: About 1 year.

  2. Incidence of left ventricular ejection fraction (LVEF) <50%.

    Time frame: About 1 year.

Secondary outcomes

  1. The change in cardiac troponin from baseline.

    Time frame: Week 24 and Week 52.

  2. The change in N-terminal B-type natriuretic peptide (NT-proBNP) from baseline.

    Time frame: Week 24 and Week 52.

07

Study locations

1 of 1 sites recruiting
  • Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
    Beijing, Beijing Municipality 100037, China
    Recruiting
    • Lianming Kang · Contactlianmingkang@126.com · +86-010-88396870
    • Lianming Kang · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 29 months after the start.

Of 20 phase 2 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 43. This study's planned 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2025
First posted
Jun 15, 2025
StartActual
Jul 4, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07021963
Responsible party
Sponsor
First posted
Jun 15, 2025
Start date
Jul 4, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 10, 2025

Study contacts

Jianhong Lv
Contact
jianhong.lv.jl9@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-1893

Start the discussion